"The Buzz" Show: Ocuphire Pharma (NASDAQ: OCUP) Phase 2 Study Endpoint in Presbyopic Patients | Financial Buzz"The Buzz'' Show: Ocuphire Pharma (NASDAQ: OCUP) Phase 2 Study Endpoint in Presbyopic Patients
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Ocuphire Pharma, Inc (NASDAQ: OCUP) Surges After VEGA-1 Phase 2 Trial Met Study Endpoints In Presbyopic Patients” Ocuphire Pharma, Inc. (NASDAQ: OCUP) surged over 40% in premarket trading after the company’s VEGA-1 Phase 2 Trial in Presbyopia Met its Primary and Secondary Endpoints. Key secondary endpoints on visual acuity and pupil diameter showed statistical significance and the Company now plans to advance into Phase 3 registration trials. Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage o...
Source: financialbuzz.com